Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Business Wire•13/10/2026•07:30 ET
0
Key Highlights
- ➤Natera (NTRA) and TransCode (RNAZ) launch CRC Phase 2a trial collaboration
- ➤Signatera will identify MRD-positive patients without radiographic disease for enrollment
- ➤TTX-MC138 targets miR-10b in metastatic cancers, including colorectal cancer
- ➤PRE-I-SPY expands beyond breast cancer into colorectal cancer for first time
Expert Statements
Philippe P. Calais, Chairman and CEO, TransCode Therapeutics
“Identifying recurrence of colorectal cancer before it becomes clinically apparent, when it is potentially much easier to treat, is one of the central challenges in developing breakthrough therapies that help to answer unmet medical needs for this setting”
Philippe P. Calais, Chairman and CEO, TransCode Therapeutics
“Leveraging one of the most established MRD testing footprints will help us identify high-risk patients faster and potentially intervene earlier, advancing a new treatment paradigm focused on addressing cancer at the molecular residual disease stage before recurrence becomes clinically apparent.”
Eric Matthews, General manager, biopharma, Natera
“We are pleased to collaborate with TransCode to bring the power of Signatera to bear on one of the most difficult problems in clinical development: finding the right patients at the right time”
Eric Matthews, General manager, biopharma, Natera
“By identifying Signatera MRD-positive patients for enrollment, we aim to support the advancement of this promising therapy for patients and build on the growing clinical and scientific momentum supporting MRD-guided strategies in colorectal cancer.”
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment
Get started
Create a free account to read the full story.